-
公开(公告)号：US20080039504A1
公开(公告)日：2008-02-14
申请号：US11775601
申请日：2007-07-10
申请人： Trevor Charvat , Cheng Hu , Jeff Jin , Yandong Li , Anita Melikian , Andrew Pennell , Sreenivas Punna , Solomon Ungashe , Yibin Zeng
发明人： Trevor Charvat , Cheng Hu , Jeff Jin , Yandong Li , Anita Melikian , Andrew Pennell , Sreenivas Punna , Solomon Ungashe , Yibin Zeng
IPC分类号： A61K31/44 , A61P43/00 , C07D401/00
CPC分类号： C07D401/14
摘要： Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要翻译： 提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。 动物试验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照 。
-
公开(公告)号：US20080039465A1
公开(公告)日：2008-02-14
申请号：US11775585
申请日：2007-07-10
申请人： Trevor Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew Pennell , Sreenivas Punna , Edward Sullivan , Xuefei Tan , William Thomas , Solomon Ungashe , Yibin Zeng
发明人： Trevor Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew Pennell , Sreenivas Punna , Edward Sullivan , Xuefei Tan , William Thomas , Solomon Ungashe , Yibin Zeng
IPC分类号： A61K31/4196 , A61K31/422 , A61K31/454 , A61K31/496 , A61K31/5377 , A61P29/00 , A61P3/00 , A61P37/00 , A61P9/00 , A61P9/10 , C07D249/08 , C07D403/04 , C07D403/06 , C07D405/04 , C07D413/04 , C07D413/06
CPC分类号： C07D249/08 , C07D401/04 , C07D403/04 , C07D405/04 , C07D413/04
摘要： Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要翻译： 提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。 动物试验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照 。
-
公开(公告)号：US08445518B2
公开(公告)日：2013-05-21
申请号：US12708900
申请日：2010-02-19
申请人： Trevor T. Charvat , Cheng Hu , Jeff Jin , Yandong Li , Anita Melikian , Andrew M. K. Pennell , Sreenivas Punna , Solomon Ungashe , Yibin Zeng
发明人： Trevor T. Charvat , Cheng Hu , Jeff Jin , Yandong Li , Anita Melikian , Andrew M. K. Pennell , Sreenivas Punna , Solomon Ungashe , Yibin Zeng
IPC分类号： A61K31/4439 , C07D401/00
CPC分类号： C07D401/14
摘要： Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要翻译： 提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。 动物试验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照 。
-
公开(公告)号：US20100152186A1
公开(公告)日：2010-06-17
申请号：US12708900
申请日：2010-02-19
申请人： Trevor T. Charvat , Cheng Hu , Jeff Jin , Yandong Li , Anita Melikian , Andrew M.K. Pennell , Sreenivas Punna , Solomon Ungashe , Yibin Zeng
发明人： Trevor T. Charvat , Cheng Hu , Jeff Jin , Yandong Li , Anita Melikian , Andrew M.K. Pennell , Sreenivas Punna , Solomon Ungashe , Yibin Zeng
IPC分类号： C07D401/04 , A61K31/4439 , C07D401/14 , A61K31/454 , A61K31/444 , C07D413/14 , A61K31/5377 , A61P9/10 , A61P21/00 , A61P1/00 , A61P13/12 , A61P19/02 , A61P3/04 , A61P11/00 , A61P35/00 , A61K31/437 , C07D487/04
CPC分类号： C07D401/14
摘要： Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要翻译： 提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。 动物试验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照 。
-
公开(公告)号：US07683176B2
公开(公告)日：2010-03-23
申请号：US11775601
申请日：2007-07-10
申请人： Trevor T. Charvat , Cheng Hu , Jeff Jin , Yandong Li , Anita Melikian , Andrew M. K. Pennell , Sreenivas Punna , Solomon Ungashe , Yibin Zeng
发明人： Trevor T. Charvat , Cheng Hu , Jeff Jin , Yandong Li , Anita Melikian , Andrew M. K. Pennell , Sreenivas Punna , Solomon Ungashe , Yibin Zeng
IPC分类号： C07D401/04
CPC分类号： C07D401/14
摘要： Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要翻译： 提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。 动物试验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照 。
-
公开(公告)号：US20070037794A1
公开(公告)日：2007-02-15
申请号：US11486974
申请日：2006-07-14
申请人： Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew Pennell , John Wright
发明人： Solomon Ungashe , Zheng Wei , Arindrajit Basak , Trevor Charvat , Wei Chen , Jeff Jin , Jimmie Moore , Yibin Zeng , Sreenivas Punna , Daniel Dairaghi , Derek Hansen , Andrew Pennell , John Wright
IPC分类号： A61K31/55 , A61K31/541 , A61K31/5377 , A61K31/496 , A61K31/444 , C07D417/14 , C07D413/14 , C07D403/14
CPC分类号： A61K31/444 , A61K31/437 , A61K31/4439 , A61K45/06 , C07C311/21 , C07D213/75 , C07D241/22 , C07D401/06 , C07D401/10 , C07D407/04 , C07D409/12 , C07D413/06 , C07D417/12 , C07D471/04 , C07D498/04
摘要： Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
摘要翻译： 提供了作为CCR2受体的有效拮抗剂的化合物。 动物实验表明，这些化合物可用于治疗炎症，CCR2的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病的方法，以及用于鉴定CCR2拮抗剂的测定中的对照。
-
公开(公告)号：US20120165303A1
公开(公告)日：2012-06-28
申请号：US13411171
申请日：2012-03-02
申请人： Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M.K. Pennell , Sreenivas Punna , Edward J. Sullivan , Xuefei Tan , William D. Thomas , Solomon Ungashe , Yibin Zeng
发明人： Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M.K. Pennell , Sreenivas Punna , Edward J. Sullivan , Xuefei Tan , William D. Thomas , Solomon Ungashe , Yibin Zeng
IPC分类号： A61K31/4196 , C07D405/04 , C07D403/04 , C07D401/04 , A61K31/454 , C07D413/04 , C07D413/06 , A61K31/5377 , A61K31/497 , A61P9/10 , A61P9/00 , A61P25/00 , A61P1/00 , A61P13/12 , A61P29/00 , A61P3/04 , A61P3/10 , A61P11/00 , A61P37/06 , A61P35/00 , A61K31/4439 , C07D403/06 , C07D487/04 , A61K31/519 , C07D249/08
CPC分类号： C07D249/08 , C07D401/04 , C07D403/04 , C07D405/04 , C07D413/04
摘要： Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要翻译： 提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。 动物试验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照 。
-
公开(公告)号：US07718683B2
公开(公告)日：2010-05-18
申请号：US11775585
申请日：2007-07-10
申请人： Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Sreenivas Punna , Edward J. Sullivan , Xuefei Tan , William D. Thomas , Solomon Ungashe , Yibin Zeng
发明人： Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Sreenivas Punna , Edward J. Sullivan , Xuefei Tan , William D. Thomas , Solomon Ungashe , Yibin Zeng
IPC分类号： A61K31/41 , C07D207/00
CPC分类号： C07D249/08 , C07D401/04 , C07D403/04 , C07D405/04 , C07D413/04
摘要： Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要翻译： 提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。 动物试验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照 。
-
公开(公告)号：US08153818B2
公开(公告)日：2012-04-10
申请号：US12753342
申请日：2010-04-02
申请人： Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Sreenivas Punna , Edward J. Sullivan , Xuefei Tan , William D. Thomas , Solomon Ungashe , Yibin Zeng
发明人： Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Sreenivas Punna , Edward J. Sullivan , Xuefei Tan , William D. Thomas , Solomon Ungashe , Yibin Zeng
IPC分类号： C07D249/00
CPC分类号： C07D249/08 , C07D401/04 , C07D403/04 , C07D405/04 , C07D413/04
摘要： Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要翻译： 提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。 动物试验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照 。
-
公开(公告)号：US08481579B2
公开(公告)日：2013-07-09
申请号：US13411171
申请日：2012-03-02
申请人： Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Sreenivas Punna , Edward J. Sullivan , Xuefei Tan , William D. Thomas , Solomon Ungashe , Yibin Zeng
发明人： Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Sreenivas Punna , Edward J. Sullivan , Xuefei Tan , William D. Thomas , Solomon Ungashe , Yibin Zeng
IPC分类号： A61K31/44 , A61K31/50 , C07D207/04 , C07D249/00
CPC分类号： C07D249/08 , C07D401/04 , C07D403/04 , C07D405/04 , C07D413/04
摘要： Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要翻译： 提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。 动物试验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照 。
-
-
-
-
-
-
-
-
-
搜索结果
51 条记录 (耗时 0.044 秒)
